Skip directly to Accessibility Notice
UCTCURE VanEck Genomics and Healthcare Innovators UCITS ETF | CURE Please read important disclosure Close important disclosure true uk en false false

Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF | CURE

Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF | CURE

  • NAV
    --

    as of 08 Dec 2023
  • YTD RETURNS
    --

    as of 08 Dec 2023
  • Total Net Assets
    --

    as of 08 Dec 2023
  • Total Expense Ratio
    0.35%
  • Inception Date
    02 Sep 2022
  • SFDR Classification
    Article 9

Overview

Fund Description

Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.

  • Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
  • Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
  • Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk Factors: Equity market risk, industry concentration risk, risk of investing in smaller companies, technological risk. Please refer to the

KIID

and the Prospectus for other important information before investing.



Underlying Index

MVIS® Global Future Healthcare ESG Index (MVFHCTR)

Performance

Holdings

Portfolio

Literature

Index